MOH said studies conducted in other countries have shown promising results.
Subscribe to our Telegram channel for the latest stories and updates.
Malaysia has been selected to be part of Phase 3 clinical trials of the Sinovac Covid-19 vaccine for children aged 12 and under, according to Deputy Health Minister II, Datuk Aaron Ago Dagang.
The vaccine is developed by Sinovac Biotech Limited – a pharmaceutical company from China which is involved in the research, development, manufacturing of vaccines.
He was quoted by Astro Awani saying that the study would begin at the end of this month and involve 10 locations:
- Eight Ministry of Health (MOH) facilities
- Universiti Malaya (UM)
- Universiti Teknologi Mara (UiTM)
Aaron Ago said the study will be coordinated by Clinical Studies Malaysia (CRM) with the involvement of the Clinical Research Institute.
Several discussion sessions were held by the Ministry of Health with COVID-19 vaccine manufacturing companies to obtain the current status and data related to the effectiveness and safety of vaccine use for children under 12 years of age. Although it has not yet received the required data from Covid-19 vaccine manufacturers so far, the Vaccine Candidate Selection Committee (JKPCV), MOH is examining the effectiveness and safety of the vaccine on the population based on scientific evidence through clinical studies or real world data.Deputy Health Minister II Datuk Aaron Ago Dagang
He said this while answering a question from Wong Kah Woh (PH-Ipoh Timur) on the suitability and effectiveness of using vaccines for children aged 12 and under.
Commenting further, Aaron Ago informed that several clinical studies are being and have been conducted globally.
On September 20, 2021 Pfizer-BioNTech released their findings for Phase 3 clinical study for children aged five to 12 years and the vaccine was found to be safe and showed a strong neutralizing antibody response. Furthermore, based on a press release from Pfizer and BionTech on October 15, 2021, the clinical study data was submitted to the US and European Food and Drug Administration (FDA) European Medicines Agency (EMA).Deputy Health Minister II Datuk Aaron Ago Dagang
In addition, he said, China has approved two vaccines produced by Sinovac Biotech Ltd. and Sinopharm for emergency use for those aged three up to 17 years old.
He also mentioned that Phase 1 and 2 clinical studies conducted by these companies found that the vaccine was safe and is able to stimulate a strong immune response in children and adolescents against the virus.
Unkempt in both stories and appearance, Hakim loves tech but tech left him on read, previously he used to write about tall buildings and unoccupied spaces that he can't afford, and legend has it that he still can't afford it to this day